Bylund James, Chief Operating Officer of Repligen Corporation (RGEN), has demonstrated a clear selling bias in recent years, with $2.64 million in total sales compared to just $88,670 in purchases across 24 transactions. The vast majority of these transactions involved RGEN, the only company in which James has reported trades. His most significant sales include an $866,204 disposition on February 23, 2024, and a $331,301 sale on November 18, 2025. The pattern shows consistent selling activity, with two additional sales recorded in early 2026—$304,052 on March 2 and $190,263 on February 27—reinforcing the trend.
James’s acquisitions have been minimal, with the only notable purchase being an $88,670 open-market buy on February 23, 2024, the same day as his largest sale. Most other transactions were smaller, non-open-market acquisitions (coded "F"), such as a $24,927 transaction on March 13, 2025, and a $19,252 purchase on March 3, 2025. The absence of recent buys—coupled with the two sales in early March 2026—suggests a continued reduction in his RGEN holdings. While some transactions appear to be routine, such as those tied to equity awards (coded "A"), the overall trend leans decisively toward divestment rather than accumulation.
AI-assisted summary